People with severe pulmonary arterial hypertension (PAH) who respond strongly to early treatment with prostacyclin infusions may eventually be able to reduce or discontinue the therapy while maintaining long-term improvements, according to a study. In a long-term analysis of 101 patients with severe PAH, about one in five improved enough...

Modena, Italy – What are nanoplastics and microplastics doing in the cerebrospinal fluid of people with ALS? And how did they manage to reach the brain? These are among the questions researchers at the University of Modena and Reggio Emilia (Unimore) are now investigating after identifying and measuring plastic particles...

PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor...